Drug intelligence / Profile preview

ENB-105

Development stage: Unknown
Lead developer: Shanghai Ennovabio Pharmaceuticals
Modality: Small Molecules

Overview

ENB-105 is a small molecule drug candidate under development by Shanghai Ennovabio Pharmaceuticals (EnnovBio) for the treatment of inflammatory bowel disease (IBD) and immune checkpoint inhibitor colitis (ICI-colitis). The drug is being developed using EnnovBio's eSTEM systems biology platform. As of early 2025, ENB-105 is in Phase 1 clinical trials for IBD. Detailed information about its precise mechanism of action or molecular target has not been disclosed publicly[1][2][3].

Beyond the preview

Go deeper on ENB-105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENB-105.

Explore the full profile